Investing in life science: From seed to success

On September 12, BioStock together with Vator Securities will host an investment focused event in Stockholm, covering the various capital needs in a life science company’s life cycle, as well as highlighting the demands and expectations from investors who provide the funds.

From early-stage investments, where business angels and seed investors drive medical breakthroughs, to growth-stage investments empowering promising ventures to become ready for partnering and/or fueling market expansion and later-stage strategic investments accelerating growth and facilitating a global market presence. The “Investing in life science: From seed to success” event caters to life science companies in all development stages, who will gain insight from investors in the various life cycle stages, as well as giving investors a chance to pick the brains of peers, engage in thought-provoking discussions and meet life science companies in early-to-commercial stages.

Further details will be presented shortly. Until then, make sure to save the date and mark September 12 in your calendar. Or even better: sign up today to secure your spot!   

Investing in life science: From seed to success is co-hosted by Vator Securities. 

Apply to attend the event via the form below. Please note that BioStock reserves the right to prioritize among ticket applicants, to ensure optimal relevance for all attendants. Priority will go to investors and company representatives.

Event Partners

Potter Clarkson is one of Europe’s leading full-service IP law firms. 

Our sole objective is to help innovators and investors maximise the value of their business or investments by identifying, protecting, exploiting, and enforcing the required IP rights anywhere in the world.

With regards to biotechnology and the life sciences, our team is one of Europe’s largest.  We are fiercely proud of our reputation as the European IP firm of choice for clients of all sizes, from ambitious start-ups and SMEs through to Big Pharma.

Having worked alongside investors in the Nordics, Germany, and the UK for decades we also know to deliver the comprehensive and commercial view of the IP in an investment required to support the best investment decisions.

With more than 90 pct. of all US biotech, pharma & life science companies listed on Nasdaq, we know how to match savvy investors with trail-blazing inventors.

We are here to support your ideas and the next steps to a public offering that keeps you in control while raising capital to ignite your ambition. By the way, if you want to keep your ambition closer to home, Nasdaq in the Nordic is the leading hub for listed biotech and health care companies in Europe, with strong support from investors and innovation communities across the region.

How to join the Nasdaq family? – Read more here: https://www.nasdaq.com/solutions/listings/markets/nordic/main-market

The Aixial Group is an International Contract Research Organization (CRO), a member of the ALTEN Group, providing services in phase I-IV clinical trials and non-interventional studies. The CRO occupies a unique position in the clinical research industry, supporting biotech across all phases, as an expert in the operational delivery of clinical trials.

Our vision is to conduct clinical trials better than anyone else to help patients and ultimately save lives. We have earned a strong reputation for successfully delivering complex, demanding and innovative clinical trials, with specialist therapeutic expertise in oncology, cell & gene therapy and rare diseases.